Glox Therapeutics is set to receive a share of the £3m ($3.67m) Collaborative Discovery Programme (CDP) funding introduced by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate. The ...
Glox Therapeutics will receive up to £500,000 of the fund to accelerate the development of its novel precision antibiotics, helping to address the growing need for effective treatments to ...
Glasgow, UK, 11 February 2025: Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced the appointment of ...